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Abstract
Background: This study compared 1-year risk of psychiatric hospitalization and treatment costs in commercially
insured patients with bipolar disorder, treated with aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone.
Methods: This was a retrospective propensity score-matched cohort study using the Ingenix Lab/Rx integrated
insurance claims dataset. Patients with bipolar disorder and 180 days of pre-index enrollment without antipsychotic
exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial
antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-
dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma
regression compared post-index costs between treatment groups.
Results: Compared to aripiprazole, ziprasidone, olanzapine and quetiapine had higher risks for hospitalization
(hazard ratio 1.96, 1.55 and 1.56, respectively; p < 0.05); risperidone had a numerically higher but not statistically
different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for aripiprazole
compared with ziprasidone (p = 0.004) and quetiapine (p = 0.007), but not compared to olanzapine (p = 0.29) or
risperidone (p = 0.80). Total healthcare costs were significantly lower for aripiprazole compared to quetiapine (p =
0.040) but not other comparators.
Conclusions: In commercially insured adults with bipolar disorder followed for 1 year after initiation of atypical
antipsychotics, treatment with aripiprazole was associated with a lower risk of psychiatric hospitalization than
ziprasidone, quetiapine, olanzapine and risperidone, although this did not reach significance with the latter.
Aripiprazole was also associated with significantly lower total healthcare costs than quetiapine, but not the other
comparators.
Background
Bipolar disorder is a chronic, recurring disorder
associated with periodic disruptions in mood regulation,
with annual treatment costs of $7,200 to $12,100 per
year, 20% of which are attributable to hospitalizations
[1,2]. Acute mania may require hospitalization for stabi-
lization of behavioral dyscontrol, irritability, and risk-
taking behavior. Despite the availability of multiple
approved medication therapies, more than 75% of
patients with bipolar disorder report at least one lifetime
psychiatric hospitalization [3].
Medication treatment patterns are variable in the
acute and long-term management of bipolar disorder,
with 42-64% of patients receiving mood stabilizers, such
as lithium, valproate or carbamazapine, and 44-60%
receiving adjunctive antipsychotics [4-6]. Atypical anti-
psychotics are used alone or in combination with mood
stabilizers for more severe manic episodes [7-11]. More-
over, adjunctive mood stabilizer-atypical antipsychotic
combination treatments may help to prevent psychiatric
hospitalization in bipolar disorder [12].
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tive aripiprazole was found to be associated with a
longer time to initial psychiatric hospitalization than
ziprasidone, olanzapine, quetiapine and risperidone dur-
ing the first 90 days following initiation [13]. A subse-
quent analysis found that total healthcare expenditures
were lower for aripiprazole than ziprasidone, olanzapine
and risperidone, and mental health expenditures were
lower for aripiprazole than all comparators [14].
The objective of the current study was to assess the
1-year risk of psychiatric hospitalization and associated
treatment costs in commercially insured patients with
bipolar disorder newly treated with aripiprazole, ziprasi-
done, olanzapine, quetiapine or risperidone, alone or in
combination with mood stabilizers.
Methods
Study design
The study was a retrospective cohort study utilizing the
Ingenix I3/LabRx claims dataset from 1/1/2003 through
12/31/2006. The dataset is a proprietary sample of indi-
viduals receiving health insurance benefits from United
Health Care (UHC). UHC data include the inpatient,
outpatient and prescription drug claims of more than 15
million of covered lives across the United States. The
index date was the date of the first prescription claim
for an atypical antipsychotic. Patients were followed for
up to 1 year post-index. Because the dataset in this
study was derived from an insurance claim database and
the data conform to the Health Insurance Portability
and Accountability Act of 1996 confidentiality require-
ments, the study did not require informed consent or
institutional review board approval.
Inclusion criteria
The study included outpatients aged 18-65 years with an
ICD-9 code for bipolar disorder, manic, mixed or hypo-
manic (296.0x, 296.1, 296.4x, 6x, 7x, 8x). Eligible
patients required at least 180 days or continuous health
plan enrollment before, and 365 days after, the index
date. Patients were included only if they were treated on
a single atypical antipsychotic at index.
Exclusion criteria
Patients were excluded from the analysis if they resided
in a nursing home, hospice, or another type of long-
term care facility, received mail-order prescriptions, or
were diagnosed with a schizophrenia spectrum disorder
(295.xx) during the pre- or post-index study period.
Patients were also excluded if they used any atypical
antipsychotic in the 180-day pre-index period, or had
prescriptions for more than one atypical antipsychotic at
index. Additionally, patients were also excluded if they
were hospitalized within 7 days of their index
antipsychotic prescription, in order to reduce treatment
selection bias based on extreme agitation or instability.
Assessments and statistical analyses
The primary outcome of interest was the first psychia-
tric hospitalization in the follow-up period. Patients
were censored for the following events: medical hospita-
lization, discontinuation of index antipsychotic (>15
days gap in coverage), or a prescription for a different
antipsychotic during the follow-up period.
In order to control for treatment selection bias, we
employed propensity score matching to construct
comparison groups that shared similar demographic
and clinical characteristics. Propensity score matching
is a robust means of controlling for observed con-
founding in observational data [15]. Propensity scores
were calculated for each patient using logistic regres-
sion with independent variables of age, sex, region,
pre-index diagnosis or treatment of diabetes or hyper-
lipidemia, pre-index psychiatric hospitalization, pre-
index lipid or glucose laboratory claims, choice of
pre-index mood stabilizer exposure and Charlson
comorbidity index. The propensity score was the pre-
dicted probability of treatment calculated for each
patient in the regression model. Patients in compari-
son treatment groups were matched 1:1 if their pro-
pensity scores were within 0.25 standard deviations of
the logit of the propensity score. All analyses were
conducted in propensity score-matched cohorts of the
study sample.
The primary analysis used Cox proportional hazards
regression to assess time-dependent risk of post-index
psychiatric hospitalization with a pre-specified thresh-
old for statistical significance of p < 0.05. Covariates
for adjustment in the models included age, sex, diag-
nosis or treatment for diabetes or hyperlipidemia diag-
nosis, pre-index psychiatric hospitalization, pre-index
lipid or glucose laboratory claims, choice of pre-index
mood stabilizer and the Deyo Charlson comorbidity
index [16]. Intent-to-treat analysis was used for the
cost analysis. Monthly treatment costs during the fol-
low-up period were compared using generalized
gamma regression controlling for pre-index costs in
patients with positive post-index healthcare costs. First,
we calculated the mean for each of the numeric covari-
ates, and gave equal share of the categorical covariates,
and then calculated the log mean of the fitted gamma
distribution based on these covariate values and the
parameter estimates and then exponentiated the log
mean to get the cost in dollars. Gamma regressions
were used to compare outcomes because gamma distri-
bution is suggested by many as a close approximation
of cost data. For example, Diehr and colleagues com-
pared different methods to model healthcare cost data
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individual covariates on total costs, the gamma distri-
bution might be preferred because it is a multiplicative
model [17]. Generalized gamma regression has been
found to be a more robust estimator than traditional
ordinary least squares regression in the analysis of
healthcare expenditure data due to the distributional
qualities of healthcare costs [18]. Only patients with
positive healthcare costs in the follow-up period were
included in the analysis, which categorized costs into
mental health (inpatient/ER and outpatient), medical
(inpatient/ER and outpatient) and pharmacy (all medi-
cations used). We excluded patients with non-positive
costs based on the assumption that patients taking
medications were also receiving billable services and
that the absence of such costs reflected aberrant data.
As a sensitivity analysis, we also replicated all multi-
variate regression analyses on the full unmatched
samples.
Results
Patient disposition and characteristics
Of 198,919 patients with at least one atypical antipsycho-
tic prescription, 7,169 met full inclusion criteria
(Figure 1). Of these, 776 patients were on aripiprazole,
492 on ziprasidone, 1,919 on olanzapine, 2,497 on
quetiapine and 1,485 on risperidone. Propensity score-
matching enabled matching of: 461 aripiprazole and
ziprasidone patients; 737 aripiprazole and olanzapine
patients; 770 aripiprazole and quetiapine patients; and
771 aripiprazole and risperidone patients. Baseline char-
acteristics after matching are shown in Table 1, demon-
strating that comparable baseline characteristics were
seen across all propensity score-matched treatment
groups.
Clinical outcomes
Table 2 describes the disposition and dosing for patients
in each treatment group. Hospitalization rates among
Treated with atypical antipsychotics
N=198,919
18-65
Not treated with clozapine
No mail order prescriptions
6 months pre-index enrollment
12 months post-index enrollment
N=33,717
No nursing home or hospice care
Bipolar Disorder
No Schizophrenia Codes
N=7,169
Outpatient at least 7 days post-index
N=32,588
Aripiprazole
N=776
Ziprasidone
N=492
Olanzapine
N=1,919
Quetiapine
N=2,497
Risperidone
N=1,485
Figure 1
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Page 3 of 9Table 1 Baseline and pre-index characteristics of propensity score-matched study sample
Variable Aripiprazole
(n = 461)
Ziprasidone
(n = 461)
p-value Aripiprazole
(n = 737)
Olanzapine
(n = 737)
p-value Aripiprazole
(n = 770)
Quetiapine
(n = 770)
p-value Aripiprazole
(n = 771)
Risperidone
(n = 771)
p-value
Age, mean (SD) 37.4 (11.6) 37.9 (11.1) 0.514 37.5 (12.0) 37.7 (11.9) 0.758 37.1 (11.9) 36.5 (11.4) 0.315 37.1 (11.9) 37.1 (11.2) 0.998
Sex, n (% men) 337 (73.1) 333 (722) 0.995 483 (65.5) 467 (63.4) 0.384 515 (66.9) 541 (70.3) 0.154 515 (66.8) 511 (66.3) 0.829
Psychiatric hospitalization, n (%) 159 (34.5) 160 (34.7) 0.945 179 (24.3) 182 (24.7) 0.856 178 (23.1) 178 (23.1) 1.000 180 (23.3) 180 (23.3) 1.000
Diabetes, n (%) 36 (7.8) 33 (7.2) 0.707 40 (5.4) 47 (6.4) 0.439 45 (5.8) 38 (4.9) 0.430 45 (5.8) 44 (5.7) 0.913
Hyperlipidemia, n (%) 75 (16.3) 81 (17.6) 0.598 123 (16.7) 131 (17.8) 0.581 130 (16.9) 130 (16.9) 1.000 130 (16.9) 119 (15.4) 0.446
Mood stabilizer exposure, n (%):
Carbamazapine 13 (2.8) 15 (3.3) 0.701 25 (3.4) 27 (3.7) 0.778 28 (3.6) 29 (3.8) 0.893 27 (3.5) 29 (3.8) 0.893
Lamotrigine 72 (15.6) 75 (16.3) 0.787 116 (15.7) 115 (15.6) 0.943 137 (17.8) 134 (17.4) 0.841 136 (17.6) 134 (17.4) 0.841
Lithium 67 (14.5) 70 (15.2) 0.781 106 (14.4) 104 (14.1) 0.882 115 (14.9) 108 (14.0) 0.612 115 (14.9) 108 (14.0) 0.612
Oxcarbazepine 34 (7.4) 38 (8.2) 0.623 60 (8.1) 65 (8.8) 0.640 75 (9.7) 68 (8.8) 0.539 75 (9.7) 68 (8.8) 0.539
Topiramate 43 (9.3) 46 (10.0) 0.738 68 (9.2) 65 (8.8) 0.785 81 (10.5) 85 (11.0) 0.742 80 (10.4) 85 (11.0) 0.742
Valproate 83 (18.0) 84 (18.2) 0.932 159 (21.6) 156 (21.2) 0.849 165 (21.4) 168 (21.8) 0.853 165 (21.4) 168 (21.8) 0.853
Charlson comorbidity index,
mean (SD)
0.3 (0.7) 0.4 (0.9) 0.388 0.3 (0.7) 0.3 (0.8) 0.432 0.2 (0.6) 0.2 (0.7) 0.746 0.3 (0.8) 0.3 (0.8) 0.468
P-values were calculated based on t-tests for continuous variables and chi square tests for categorical variables.
Table 2 Patient disposition and dosing - study sample
Psychiatric
Hospitalization
Medical
Hospitalization
Add/Switch
Antipsychotic
Discontinued
Antipsychotic
Completed
Follow-up
Duration of Antipsychotic
Treatment
Starting Daily
Dose
Maximum Daily
Dose
Index
Antipsychotic
N N (%) N (%) N (%) N (%) N (%) Median days
(Q1, Q3)
Mean mg
(SD)
Mean mg
(SD)
Aripiprazole 461 35 (7.6) 8 (1.7) 28 (6.1) 379 (82.2) 11 (2.4) 30 (30, 71) 11.8 (6.7) 13.4 (8.5)
Ziprasidone 461 59 (12.8) 11 (2.4) 66 (14.3) 307 (66.6) 18 (3.9) 30 (30, 70) 83.2 (49.7) 95.5 (57.2)
Aripiprazole 737 47 (6.4) 11 (1.5) 48 (6.5) 609 (82.6) 22 (3.0) 30 (30, 72) 11.2 (6.5) 12.9 (8.1)
Olanzapine 737 66 (9.0) 14 (1.9) 37 (5.0) 603 (81.8) 17 (2.3) 30 (30, 63) 7.8 (5.4) 8.7 (5.8)
Aripiprazole 770 48 (6.2) 10 (1.3) 49 (6.4) 640 (83.1) 23 (3.0) 30 (30, 72) 11.2 (6.5) 12.8 (8.1)
Quetiapine 770 78 (10.1) 8 (1.0) 34 (4.4) 619 (80.4) 31 (4.0) 30 (30, 73) 140.3 (146.1) 172.2 (200.6)
Aripiprazole 771 49 (6.4) 11 (1.4) 49 (6.4) 639 (82.9) 23 (3.0) 30 (30, 71) 12.8 (8.1) 12.8 (8.1)
Risperidone 771 72 (9.3) 14 (1.8) 59 (7.7) 603 (78.2) 23 (3.0) 30 (30, 73) 1.6 (1.3) 1.6 (1.3)
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9patients treated with aripiprazole ranged from 6.2 to
7.4% depending on the matched cohort, whereas com-
parators ranged from 9.3 to 12.8%. More than two-
thirds of all patients discontinued their index antipsy-
chotic during the 1-year follow-up period, and less than
5% completed a full year of follow-up taking their index
antipsychotic medication. The duration of therapy on
atypical antipsychotics was comparable across all treat-
ment groups and fairly brief, with a median of 30 days
across all treatments. Starting and maximal doses were
relatively similar, suggesting limited titration after
initiation.
Fully adjusted Cox proportional hazards analysis
demonstrated that treatment with aripiprazole was asso-
ciated with a significantly lower risk of hospitalization
than ziprasidone, olanzapine and quetiapine, and not
significantly different than risperidone. Table 3 sum-
marizes the results of these models, in which pre-index
psychiatric hospitalization was significantly associated
with risk of post-index hospitalization in all models. The
number of pre-index mood stabilizers was not signifi-
cantly associated with risk of hospitalization. Gender
a n da g ew e r en o ta s s o c i a t e dw i t hr i s ko fh o s p i t a l i z a t i o n
in any cohort. There was variability among matched
cohorts regarding the association between post-index
mood stabilizer exposure and risk of hospitalization.
Results of the analysis in unmatched samples are in
Table 4. The effects are directionally the same, statisti-
cally significant, with some effect sizes being even larger
than in the matched analyses.
Economic outcomes
Monthly post-index healthcare cost estimates derived
from the gamma regression are summarized in Table 5.
Adjusted monthly inpatient/ER mental health costs were
significantly lower in the aripiprazole-treated patients
compared with those treated with ziprasidone, olanza-
pine and quetiapine, and numerically lower than risperi-
done in those patients with inpatient costs. Total mental
health costs were lower for aripiprazole compared to
ziprasidone and quetiapine, but not significantly differ-
ent compared to olanzapine and risperidone. Compared
to aripiprazole, total medical costs were higher for
quetiapine but not significantly different for all other
comparators. Pharmacy costs were lower for olanzapine,
risperidone and quetiapine, and not significantly differ-
ent for ziprasidone. Total healthcare costs in the follow-
up period were significantly lower for aripiprazole than
quetiapine, and not significantly different for the other
comparators. Results of the analysis in unmatched
Table 3 Adjusted Cox proportionate hazards models (aripiprazole reference)
Effect Ziprasidone
Hazard Ratio
(95% CI)
Olanzapine
Hazard Ratio
(95% CI)
Quetiapine
Hazard Ratio
(95% CI)
Risperidone
Hazard Ratio
(95% CI)
Age 0.992 (0.973-1.011) 0.997 (0.981-1.014) 0.994 (0.978-1.011) 0.988 (0.971-1.005)
Women vs. Men 1.164 (0.720-1.882) 0.755 (0.510-1.118) 1.269 (0.837-1.924) 0.776 (0.524-1.149)
Charlson Comorbidity Index 1.220 (1.024-1.454)* 1.054 (0.876-1.267) 0.801 (0.548-1.171) 1.109 (0.958-1.284)
Prior Psychiatric Hospitalization 2.910 (1.888-4.484)*** 3.541(2.408-5.207)*** 3.874 (2.703-5.553)*** 2.287 (1.579-3.314)***
Prior Diabetes 0.838 (0.338-2.076) 0.885 (0.358-2.189) 2.222 (0.943-5.232) 1.149 (0.550-2.400)
Prior Hyperlipidemia 0.913 (0.446-1.317) 0.614 (0.324-1.165) 0.895 (0.508-1.579) 1.327(0.776-2.268)
Prior Lipid Test 0.677 (0.348-1.317) 0.715 (0.412-1.243) 1.307 (0.779-2.194) 0.687(0.397-1.189)
Prior Glucose Test 1.172 (0.742-1.849) 1.409 (0.928-2.141) 0.792 (0.519-1.210) 1.476 (0.969-2.248)
Pre-index mood stabilizer
1 vs. none 1.177 (0.648-2.138) 1.194 (0.679-2.098) 1.489 (0.904-2.451) 1.197(0.697-2.056)
2 vs. none 0.765 (0.270-2.171) 0.689 (0.280-1.691) 1.487 (0.704-3.142) 1.250(0.552-2.831)
≥ 3 vs. none 0.331 (0.035-3.137) 1.068 (0.291-0.919) 0.617 (0.073-5.217) 0.301(0.035-2.567)
Post-index mood stabilizer
Carbamazepine 3.853 (1.623-9.151)** 2.191(0.988-4.859) 1.242 (0.579-2.661) 1.926(0.879-4.219)
Lamotrigine 1.268 (0.640-2.514) 1.233 (0.649-2.344) 0.844 (0.486-1.465) 1.482(0.853-2.573)
Lithium 0.716 (0.317-1.619) 2.287(1.249-4.188)** 0.710 (0.377-1.339) 1.029(0.556-1.904)
Oxcarbazepine 1.660 (0.740-3.726) 1.266 (0.607-2.640) 0.469 (0.201-1.092) 0.877(0.422-1.824)
Topiramate 1.256 (0.536-2.943) 1.699 (0.847-3.407) 0.800 (0.422-1.518) 1.362(0.697-2.663)
Valproate 0.811 (0.399-1.652) 0.754 (0.402-0.414) 0.438 (0.235-0.814)** 0.679(0.364-1.266)
Year of Index Prescription 0.963 (0.733-1.266) 1.047 (0.814-0.345) 0.773 (0.617-0.969) 0.758(0.604-0.952)*
Comparator vs. Aripiprazole 1.962 (1.269-3.033)** 1.554 (1.035-1.333)* 1.556 (1.078-2.245)* 1.368(0.940-1.989)
* p < 0.05.
**p < 0.01.
***p < 0.001.
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Page 5 of 9samples are in Table 6. The effects are directionally the
same.
Discussion
This study extends findings of a previous short-term ret-
rospective cohort study that reported reduced risk of
hospitalization and lower psychiatric treatment costs of
patients with bipolar disorder treated with mood stabili-
zer and adjunctive aripiprazole compared to adjunctive
ziprasidone, olanzapine and quetiapine during a 90-day
follow-up period [13,14]. In this 1-year follow-up study,
risk of hospitalization was lower in patients treated with
aripiprazole with or without mood stabilizer compared
to ziprasidone, olanzapine and quetiapine. Duration of
therapy on atypical antipsychotic therapy was compar-
able across all atypical antipsychotics in this study,
although the duration was brief relative to the follow-up
period, lasting less than 3 months in 75% of cases. How-
ever, treatment guidelines recommend regimen simplifi-
cation after patients are stabilized [7,11]. Therefore, in
our sample, it is possible that the short duration of aty-
pical antipsychotic therapy reflects stabilization of
patients that allowed discontinuation of the atypical
antipsychotic. Gianfrancesco et al. found somewhat
longer treatment durations in a study of commercially
insured patients treated with antipsychotics, with treat-
ment durations of 7-10 months [19]. However, they
a l l o w e dag a po fu pt o1 2 0d a y sb e f o r ee n d i n gat r e a t -
ment episode, whereas our threshold of 15 days was
much more conservative. To allow for meaningful com-
parative analysis of the cost data, intent-to-treat analysis
was conducted for the cost analysis and patients were
followed up for 1 year after their initial atypical antipsy-
chotics treatment.
Antipsychotic doses observed also tended to be lower
than label-recommended doses and demonstrated little
titration over the course of treatment. These observa-
tions are consistent with other reports on atypical anti-
psychotic dosing in bipolar disorder [20,21]. Although
we are not able to determine the reasons for these dos-
ing patterns, it is possible that, due to concerns regard-
ing tolerability or safety, physicians were reluctant to
start patients on higher doses.
Along with the lower risk of psychiatric hospitaliza-
tions associated with aripiprazole compared to three of
the four comparators, patients who initiated aripiprazole
had lower psychiatric inpatient costs. These results sug-
gest that treatment with aripiprazole tends to provide a
valuable cost-offset in saving from decreased hospitaliza-
tion risk and associated inpatient costs. In particular, the
lower risk of hospitalization combined with lower total
costs compared to quetiapine represent two attractive
outcomes for formulary decision-makers responsible for
the entire costs of care [22].
Table 4 Adjusted Cox proportionate hazards models (aripiprazole reference) for unmatched samples
Effect Ziprasidone
Hazard Ratio
(95% CI)
Olanzapine
Hazard Ratio
(95% CI)
Quetiapine
Hazard Ratio
(95% CI)
Risperidone
Hazard Ratio
(95% CI)
Age 0.988 (0.971-1.006) 0.992 (0.980-1.004) 0.991 (0.980-1.001) 0.994 (0.981-1.007)
Women vs. Men 1.137 (0.735-1.759) 1.013 (0.773-1.326) 1.193 (0.928-1.533) 0.909 (0.675-1.224)
Charlson Comorbidity Index 1.168 (1.027-1.328) 1.054 (0.912-1.218) 0.988 (0.855-1.142) 1.100 (0.968-1.249)
Prior Psychiatric Hospitalization 2.805 (1.902-4.136) 3.051 (2.333-3.990) 2.777 (2.213-3.485) 2.551 (1.923-3.385)
Prior Diabetes 0.901 (0.414-1.965) 1.056 (0.550-2.026) 1.170 (0.704-1.944) 1.294 (0.738-2.269)
Prior Hyperlipidemia 1.255 (0.685-2.299) 0.834 (0.539-1.289) 0.828 (0.572-1.199) 1.162 (0.764-1.769)
Prior Lipid Test 0.641 (0.357-1.149) 0.807 (0.546-1.192) 1.000 (0.722-1.386) 1.048 (0.696-1.579)
Prior Glucose Test 1.305 (0.858-1.983) 1.288 (0.963-1.722) 1.030 (0.801-1.325) 1.132 (0.819-1.563)
Pre-index mood stabilizer
1 vs. none 1.624 (0.946-2.789) 0.735 (0.499-1.085) 0.849 (0.606-1.188) 1.310 (0.863-1.988)
2 vs. none 1.241 (0.533-2.890) 0.387 (0.196-0.764) 0.646 (0.372-1.122) 1.737 (0.925-3.263)
≥3 vs. none 0.833 (0.162-4.287) 0.434 (0.134-1.408) 0.705 (0.225-2.207) 0.304 (0.038-2.416)
Post-index mood stabilizer
Carbamazepine 2.792 (1.292-6.031) 2.741 (1.417-5.301) 1.745 (0.986-3.087) 1.482 (0.720-3.049)
Lamotrigine 1.204 (0.671-2.161) 1.765 (1.056-2.952) 1.058 (0.719-1.555) 1.273 (0.810-2.002)
Lithium 0.588 (0.298-1.159) 2.314 (1.509-3.551) 0.931 (0.626-1.385) 0.740 (0.452-1.210)
Oxcarbazepine 1.342 (0.655-2.748) 1.876 (1.034-3.403) 0.870 (0.519-1.459) 1.016 (0.584-1.766)
Topiramate 1.006 (0.493-2.051) 1.753 (0.994-3.091) 1.336 (0.844-2.117) 1.052 (0.596-1.855)
Valproate 0.646 (0.341-1.224) 1.352 (0.889-2.056) 0.824 (0.561-1.211) 0.782 (0.504-1.214)
Year of Index Prescription 0.937 (0.732-1.199) 1.032 (0.868-1.228) 0.963 (0.837-1.109) 0.959 (0.803-1.146)
Comparator vs. Aripiprazole 2.047 (1.388-3.019) 1.549 (1.098-2.184) 1.551 (1.139-2.113) 1.567 (1.124-2.186)
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Page 6 of 9Table 5 Adjusted monthly post-index costs for patients with positive costs, US dollars
Cost Category Aripiprazole
Mean $ (SE)
Ziprasidone
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Olanzapine
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Quetiapine
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Risperidone
Mean $ (SE)
p-value
Psychiatric costs
Inpatient/ER 788.70(91.60) 1039.90
(121.70)
0.076 666.90 (61.80) 876.20 (91.70) 0.038 627.60 (56.80) 833.80 (81.00) 0.024 674.40 (61.70) 743.60 (73.50) 0.446
Outpatient 202.00 (12.50) 271.90 (16.40) <0.001 191.60 (9.70) 207.00 (9.90) 0.210 194.40 (9.20) 232.30 (10.90) 0.003 195.10 (9.50) 206.30 (9.50) 0.351
Total 487.20 (33.80) 631.20 (43.60) 0.004 447.30 (24.80) 483.70 (27.50) 0.287 429.90 (22.60) 518.80 (28.00) 0.007 449.10 (24.10) 441.50 (23.70) 0.807
General medical
costs
Inpatient/ER 747.20 (115.10) 686.40 (104.30) 0.687 681.00 (86.80) 372.20 (44.50) <0.001 642.30 (83.70) 790.70 (89.70) 0.220 667.60 (87.40) 966.80 (120.30) 0.038
Outpatient 398.00 (24.60) 365.20 (23.30) 0.282 372.90 (19.30) 382.80 (20.00) 0.690 386.40 (19.60) 433.80 (21.20) 0.070 384.10 (19.20) 353.60 (17.30) 0.189
Total 540.20 (36.50) 527.10 (36.40) 0.777 521.60 (28.40) 484.60 (26.50) 0.294 519.40 (28.40) 655.70 (34.00) 0.001 511.10 (27.70) 542.10 (29.20) 0.395
Psychiatric Medical
and General Medical
costs
961.30 (59.00) 1055.10 (65.90) 0.223 910.00 (45.00) 891.20 (43.80) 0.736 875.00 (42.20) 1,060.30 (50.00) 0.001 898.20 (43.90) 934.30 (45.00) 0.518
Pharmacy costs 286.00 (11.10) 296.10 (11.40) 0.435 281.80 (9.10) 257.20 (8.00) 0.012 288.60 (9.00) 252.80 (7.70) <0.001 282.70 (8.90) 241.00 (7.20) <0.001
TOTAL COSTS 1,308.20 (64.90) 1,406.20 (70.80) 0.229 1,287.40 (51.10) 1,214.00
(47.70)
0.224 1,230.70
(47.70)
1,354.90 (51.70) 0.040 1,252.40 (49.60) 1,216.20 (47.60) 0.540
Results of generalized gamma regression adjusting for pre-index costs in propensity score-matched cohorts.
Table 6 Adjusted monthly post-index costs for unmatched patients with positive costs, US dollars
Cost Category Aripiprazole
Mean $ (SE)
Ziprasidone
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Olanzapine
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Quetiapine
Mean $ (SE)
p-value Aripiprazole
Mean $ (SE)
Risperidone
Mean $ (SE)
p-value
Psychiatric Medical
costs
Inpatient/ER 678.00(61.10) 1025.70
(117.60)
0.003 660.70 (57.90) 931.10 (63.60) 0.001 665.50 (58.40) 859.40 (46.80) 0.010 667.00 (58.00) 786.50 (54.90) 0.121
Outpatient 189.30 (9.20) 267.80 (15.30) <0.001 185.70 (8.80) 208.30 (6.70) 0.024 200.20 (8.80) 235.30 (6.50) 0.001 196.40 (9.00) 218.10 (7.40) 0.041
Total 450.30 (23.60) 639.70 (43.60) <0.001 428.40 (22.70) 474.50 (18.50) 0.095 445.90 (22.70) 536.20 (17.40) 0.001 445.30 (22.90) 471.30 (18.80) 0.347
General Medical
costs
Inpatient/ER 648.10 (83.30) 752.00 (376.10) 0.431 635.60 (78.00) 488.90 (36.60) 0.063 665.60 (82.70) 821.60 (50.70) 0.124 664.40 (86.50) 854.80 (75.10) 0.103
Outpatient 373.90 (18.40) 376.10 (23.30) 0.931 387.40 (18.70) 366.80 (12.20) 0.312 386.90 (18.20) 434.10 (12.60) 0.025 373.10 (18.20) 363.60 (13.70) 0.646
Total 505.50 (27.00) 556.80 (36.40) 0.210 538.10 (27.30) 502.10 (17.50) 0.227 546.90 (27.90) 681.80 (21.20) <0.001 491.70 (25.80) 518.80 (21.40) 0.377
Psychiatric Medical
and General
Medical costs
887.20 (42.00) 1,066.00 (64.40) 0.007 903.80 (41.80) 895.70 (29.50) 0.861 931.00 (41.90) 1,129.40 (33.00) <0.001 883.90 (40.90) 944.80 (34.40) 0.205
Pharmacy costs 286.90 (9.00) 293.80 (10.40) 0.533 288.00 (8.70) 270.60 (5.40) 0.043 296.60 (8.70) 267.00 (5.10) <0.001 284.30 (8.30) 240.80 (5.30) <0.001
TOTAL COSTS 1,253.30 (47.50) 1,419.20 (67.80) 0.018 1,275.80 (47.10) 1,202.60 (31.70) 0.145 1,306.00 (47.50) 1,439.70 (34.80) 0.013 1,239.70 (46.50) 1,220.60 (36.50) 0.708
Results of generalized gamma regression adjusting for pre-index costs in unmatched cohorts.
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9Observational studies can provide important insights
into the outcomes of clinical practice in real-world
settings, where dosing, titration and concomitant medi-
cations are not constrained by trial protocols. Such
studies evaluate the effectiveness of treatments as they
are actually used rather than when optimally dosed. We
included the full range of observed dosing in our analy-
sis based on the assumption that, in selecting medica-
tions, physicians also use what they believe is the most
appropriate dosing and titration for that medication.
This study has several limitations. As a non-rando-
mized retrospective study of observational data, it is
possible that despite the use of propensity score match-
ing and multivariate modeling, unobserved treatment
selection bias may confound the results. Propensity
score matching, however, is a widely accepted method
for minimizing the effects of treatment selection bias in
observational data [15]. Other approaches such as
instrumental variables and Heckman’s sample selection
bias method may also be used in such settings [23,24],
although the potential for residual confounding remains
with all such methods. The consistency of our results in
propensity score-matched and unmatched samples sug-
gests that these findings are robust. However, the data-
set we analyzed consists of patients from a single
commercial health plan; results may not be applicable to
chronic populations that are more likely to be covered
by public sector insurance. Replication in other observa-
tional datasets is necessary to validate the robustness of
these results.
Additionally, by restricting the analysis to an inception
c o h o r t ,w ew e r eo n l ya b l et os t u d yt h ee f f e c t so ft h e
initial choice of medication following an antipsychotic-
free period and are thus limited to conclusions on initial
antipsychotic selection rather than the effectiveness of a
given medication under all circumstances. Based on our
results, aripiprazole appears to be the most effective
initial choice among atypical antipsychotics for the acute
treatment of bipolar disorder, and these effects appear
to persist in the post-acute phase. Finally, the study only
followed patients until their first psychiatric hospitaliza-
tion and did not address outcomes following adding,
switching, or discontinuing antipsychotics, which may
be common in this population. The analysis of such
complex treatment patterns within claims data may be
subject to high levels of unobservable confounding and
difficult to interpret with respect to the contribution of
individual medications across complex regimens. Specifi-
cally, it may be challenging to account for residual
effects of prior medications following a switch, which is
why we chose inception cohort design. Moreover, the
reasons for adding versus switching antipsychotics
would require detailed clinical information not available
in this dataset to adjust for treatment selection bias.
Therefore, our results are limited to outcomes only
while the patient is on their initial antipsychotic medica-
tion for that episode of treatment.
Conclusions
In adults with bipolar disorder, treatment with aripipra-
zole was associated with a lower risk of hospitalization
than ziprasidone, olanzapine and quetiapine, and lower
mental health costs than ziprasidone and quetiapine in
the year following initial prescription. Total healthcare
costs of patients treated with aripiprazole were lower
than those treated with quetiapine.
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